Bright Gene

BrightGene Bio-Medical Technology Co., Ltd. is a research-driven biopharmaceutical company headquartered in the Suzhou Industrial Park, China, focused on developing innovative treatments for oncology, infectious diseases, and metabolic conditions. The company conducts original drug discovery and clinical development, including a GLP1/GIP dual agonist that successfully completed Phase II clinical trials — a first in China. BrightGene also partners with global pharmaceutical and biotech organizations to expand access to medicines, including collaboration with the Medicines Patent Pool to manufacture generic formulations. With subsidiaries across multiple Chinese provinces, the company operates across both innovative drug R&D and commercial-scale pharmaceutical manufacturing.